CTOs on the Move

Asymchem Laboratories

www.asymchem.com

 
Asymchem Laboratories is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.asymchem.com
  • 600 Airport Blvd Ste 1000
    Morrisville, NC USA 27560
  • Phone: 919.468.3884

Executives

Name Title Contact Details

Similar Companies

Promius Pharma

Promius Pharma is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vista Pharmaceuticals

Vista Pharmaceuticals is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.

NEW Health Programs Association

NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify.   We believe that all people deserve...

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.